NOTRELOAD AI
  • NOTRELOAD AI
  • XYZ.
  • XY.
  • #TrumpTrade
  • Discord
  • Buy Me a Coffee →
Sign in Subscribe

Yum! Brands Q2 Challenges & Strategic Response

Yum! Brands missed Q2 targets due to rising costs and soft demand. Taco Bell slowed, KFC/Pizza Hut saw declines. Value deals and AI are key strategies.

Yum! Brands Q2 Challenges & Strategic Response
Photo by Yanhao Fang on Unsplash

This post is for paying subscribers only

Already have an account? Sign in.
08/05/2025 · 11:23 AM
YUM
/ Read more

Feed↓

Texas Instruments' Post-Tariff Sales Slump Confirmed
09/04/2025 · 11:47 AM

Texas Instruments' Post-Tariff Sales Slump Confirmed

Texas Instruments' sales slowed post-April, partly due to tariff pull-ins, sparking investor fears of a "mirage" turnaround. The CFO hinted at softer sales next year, potentially leading to production cuts, while analysts noted a cautious tone from the CEO. The market anticipates guidance cuts.

/ Subscriber only
FDA Review for Agios' PYRUKYND in Thalassemia Extended to December 2025
09/04/2025 · 8:21 AM

FDA Review for Agios' PYRUKYND in Thalassemia Extended to December 2025

The FDA extended PYRUKYND's review for thalassemia by 3 months to Dec 7, 2025, after Agios submitted a plan (REMS) to manage liver injury risk. This oral medicine aims to treat adult alpha- or beta-thalassemia.

/ Subscriber only
09/04/2025 · 8:00 AM

Aquestive's Anaphylm: Needle-Free Epinephrine on Track for FDA Approval

Anaphylm, Aquestive's needle-free sublingual epinephrine film for severe allergic reactions, is on track for FDA approval by Jan 31, 2026. It offers a device-free, orally delivered alternative to overcome needle fear.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Buy Me a Coffee
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe